The Helsana Group is the leading health and accident insurer in Switzerland. It offers individuals and companies a complete health and prevention service in the event of sickness and accidents.
Greater transparency in the supply of medicinal products
In addition to a general section, the 2018 Drug Report follows on from previous versions and offers analyses of real and supposed innovations, the dispensation of medication in the outpatient sector and the vaccination coverage rate among children. With its report, Helsana is ensuring greater transparency in the healthcare sector, and thus helping to improve the care that our customers receive.
However, not all of these products are actually innovations. The 2018 Drug Report shows that between 2014 and 2017 only a fraction of newly approved preparations represented innovations. The majority of newly approved preparations are either generics or are based on minor changes to the formulation or a name change. A further focus section shows that on average Mr and Mrs Swiss obtained eight active ingredients per year. Pharmacies are the most popular delivery channel, followed by basic suppliers, hospital outpatient clinics and specialists.
The vaccination situation among Swiss children was scrutinised in a further analysis. It was revealed that the vaccination coverage rate among children is too low as measured by the Swiss vaccination schedule: the share of non-vaccinated children is highest in the canton of Appenzell Innerrhoden, followed by Appenzell Ausserrhoden and Nidwalden. The highest vaccination rates were recorded for children in the cantons of Basel-Stadt, Geneva and Basel-Landschaft.
Unique in Switzerland
The Helsana Drug Report is unique in Switzerland. The report – compiled in cooperation with the University Hospital of Basel (USB) and the European Centre of Pharmaceutical Medicine (ECPM) at the University of Basel – provides authentic insights into the supply of medicinal products in Switzerland. We also cast a critical eye on the market for medicinal products, look for anomalies and differences, and identify room for improvement. We do so from the perspective of our customers and in our role as the "trustee" of Swiss premium payers.
Transparency takes centre stage
The report contains assessments of market trends based on our own (anonymised) statement data and provides a representative picture of the number of recipients of medication and the resulting costs. We also provide an in-depth analysis of selected indications and medication groups. The focus falls on the transparent representation of real trends.